日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comparison between [(68)Ga]Ga-FAPI-46 and [(18)F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer

比较 [(68)Ga]Ga-FAPI-46 和 [(18)F]FDG PET/CT 在管腔样乳腺癌与 HER2 阳性乳腺癌中的摄取情况

Küper, Alina Toni; Vaz, Sofia Carrilho; Pabst, Kim Magaly; Ciuciulkaite, Ieva; Mavroeidi, Ilektra Antonia; Hamacher, Rainer; Welt, Anja; Hammersen, Noah; Costa, Pedro Fragoso; Djaileb, Loic; Seifert, Robert; Umutlu, Lale; Schuler, Martin; Herrmann, Ken; Fendler, Wolfgang Peter; Kümmel, Sherko; Kersting, David

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT

完善辅助性 CDK4/6 抑制剂的风险评估,超越临床试验纳入标准:根据 ADAPT 整合复发评分和内分泌反应性

Braun, Michael; Gluz, Oleg; Kuemmel, Sherko; Nitz, Ulrike; Luedtke-Heckenkamp, Kerstin; Darsow, Maren; Forstbauer, Helmut; Polata, Silke; Grischke, Eva-Maria; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Zu Eulenburg, Christine; Kates, Ronald; Burmeister, Sandy; Graeser, Monika; Wuerstlein, Rachel; Baehner, Rick; Christgen, Matthias; Kreipe, Hans Heinrich; Harbeck, Nadia

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial

在WSG-ADAPT-TN试验中,免疫调节基因网络可预测三阴性乳腺癌患者对降阶梯、不含蒽环类药物的新辅助化疗的治疗反应和生存期。

Korbie, Darren; Stirzaker, Clare; Gluz, Oleg; Zu Eulenburg, Christine; Nitz, Ulrike; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Wuerstlein, Rachel; Pelz, Enrico; Kreipe, Hans Heinrich; Clark, Susan J; Trau, Matt; Graeser, Monika; Harbeck, Nadia

600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial

600毫克与400毫克一线瑞博西尼治疗激素受体阳性/ERBB2阴性晚期乳腺癌:AMALEE随机临床试验

Cardoso, Fatima; Jacot, William; Kuemmel, Sherko; Gupta, Sudeep; Cruz, Felipe; Balaraman, Rama; Ferreira, Ana; Ahola, Tytti; Chapko, Yana; Zhukova, Lyudmila; Chiang, Wendy; Li, Zheng; Ji, Yan; Kaakiou, Nadia; Bolotova, Natalia; Sparano, Joseph A

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders

预测性内分泌抵抗指数能够准确区分管腔型乳腺癌治疗的有效者和无效者。

Zhang, Guokun; Jurinovic, Vindi; Bartels, Stephan; Christgen, Matthias; Christgen, Henriette; Kandt, Leonie Donata; Mishieva, Lidiya; Ni, Hua; Raap, Mieke; Klein, Janin; Katzke, Anna-Lena; Hofmann, Winfried; Steinemann, Doris; Kates, Ronald E; Gluz, Oleg; Graeser, Monika; Kümmel, Sherko; Nitz, Ulrike; Plass, Christoph; Lehmann, Ulrich; Zu Eulenburg, Christine; Mansmann, Ulrich; Gerhäuser, Clarissa; Harbeck, Nadia; Kreipe, Hans H

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors

首个靶向FcγRIIB的单克隆抗体(BI-1607):HER2阳性晚期实体瘤患者的临床前数据和首次人体研究

Cortés, Javier; Priego, Araceli; Garralda, Elena; Rojas, Katerin; Lord, Simon R; Goetze, Thorsten O; Kuemmel, Sherko; Crabb, Simon J; Parra-Guillen, Zinnia P; Borggren, Marie; Karlsson, Ingrid; Lindahl, Danijela; Mårtensson, Linda; Oldham, Robert; Ropenga, Anna; Teige, Ingrid; Wallin, Johan; Frendeus, Björn; McAllister, Andres

Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

三阴性乳腺癌患者的基因改变、治疗反应和生存率:一项随机临床试验的二次分析

Richters, Lisa; Gluz, Oleg; Weber-Lassalle, Nana; Christgen, Matthias; Haverkamp, Heinz; Kuemmel, Sherko; Kayali, Mohamad; Kates, Ronald E; Grischke, Eva-Maria; Altmüller, Janine; Forstbauer, Helmut; Thiele, Holger; Braun, Michael; Warm, Mathias; Ossowski, Anna; Wuerstlein, Rachel; Ernst, Corinna; Graeser, Monika; Linn, Sabine C; Nitz, Ulrike; Hauke, Jan; Kreipe, Hans Heinrich; Schmutzler, Rita K; Hahnen, Eric; Harbeck, Nadia

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高危早期三阴性乳腺癌患者新辅助帕博利珠单抗联合化疗疗效的分子决定因素:一项开放标签、多队列 1b 期 KEYNOTE-173 研究的探索性分析

Dent, Rebecca; Cortés, Javier; Park, Yeon Hee; Muñoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kümmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

CRISPR技术在疾病管理中的应用:临床转化和治疗潜力的最新综述

Far, Bahareh Farasati; Akbari, Marziyeh; Habibi, Mohammad Amin; Katavand, Morteza; Nasseri, Sherko

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

HER2低表达状态作为一种独特的乳腺癌亚型:是谬论还是事实?对WSG试验WSG-ADAPT-HR+/HER2-、WSG-PlanB和WSG-ADAPT-TN的分析

Schmidt, Gilda; Gluz, Oleg; Christgen, Matthias; Reinisch, Mattea; Kümmel, Sherko; Nitz, Ulrike; Braun, Michael; Aktas, Bahriye; Lüdtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Schumacher, Claudia; Mahlberg, Rolf; Malter, Wolfram; Reimer, Toralf; Nuding, Benno; Stefek, Andrea; Wuerstlein, Rachel; Graeser, Monika; Jóźwiak, Katarzyna; Burmeister, Sandy; Zu Eulenburg, Christine; Lauseker, Michael; Kolberg-Liedtke, Cornelia; Prat, Aleix; Schmid, Peter; Baehner, Rick; Kreipe, Hans Heinrich; Solomayer, Erich-Franz; Harbeck, Nadia